XERSXeris Biopharma Holdings, Inc.
$10.48+36% 1Y
$10.48
$5.2952 weeks$10.48
Latest close: a new 52-week highOct 9, 2026what changed →
XERS in its own filings
Nothing in XERS's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
93
Events found in the filings · across 333 filings · the record starts in 2021
- Hard flags
- none
Hard flags
- Most recent filing
- Sep 9, 2026
Most recent filing · Form 8-K
- Record starts
- Jul 9, 2021
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- Change in certifying accountanthistorical
- 2023-03-17
- SEC comment-letter activity13 occurrences
- 2025-05-09
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 9, 2026John Shannon Becoming the Next Great Biopharmaceutical Company Chairman & Chief Executive Officer.Regulation FD disclosure · press release
- Aug 6, 2026Total revenue increased to over $92 million.Earnings release · press release
- Jun 30, 2026Appointment of Director Nerissa Kreher On June 29, 2026, the Board of Directors (the “Board”) of Xeris Biopharma Holdings, Inc. (the “Company”) increased the size of the Board from seven (7) to eight (8) members, thereby creating a vacancy on the Board, and appointed Nerissa Kreher, M.D., to fill such vacancy …Director or officer change · Form 8-K
- Jun 11, 2026On June 11, 2026, the Company issued a press release announcing entry into the Exchange Agreements.Unregistered sale of equity · Form 8-K
- May 7, 2026Total product revenue increased 43% year-over-year to over $82 million.Earnings release · press release
- Apr 21, 2026Retirement of Director Jeffrey Sherman On April 20, 2026, Dr. Jeffrey Sherman, a member of the Board of Directors (the “Board”) of Xeris Biopharma Holdings, Inc. (the “Company”), provided notice to the Company of his decision to retire from the Board and not stand for reelection at the Company’s 2026 Annual Meeting of …Director or officer change · Form 8-K
- Mar 2, 2026Achieved record quarterly and full-year total revenue of $86 million and $292 million, respectively.Earnings release · press release
- Feb 27, 2026Four Orange Book Listed Patents through March 2040.Regulation FD disclosure · press release
- Dec 1, 2025Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application.Regulation FD disclosure · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Drug Manufacturers, Specialty & Generic
Ranks #25 of 41 by RyuScore